CMEOF (Creo Medical Group) Long-Term Debt: $2.41 Mil (As of Dec. 2025)


CMEOF Creo Medical Group PLC CMEOF
53 GF Score
Price $0.20
GF Value $0.24
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Long-Term Debt?

Creo Medical Group CMEOF 53 Long-Term Debt is $2.41 Mil as of Dec. 2025. GuruFocus rates CMEOF with a GF Score™ of 53/100 and a GF Value™ of $0.24. The stock has 6 warning signs investors should review.

Creo Medical Group's Long-Term Debt for the quarter that ended in Dec. 2025 was $2.41 Mil.

Creo Medical Group's quarterly Long-Term Debt declined from Dec. 2024 ($2.40 Mil) to Jun. 2025 ($0.00 Mil) but then increased from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($2.41 Mil).

Creo Medical Group's annual Long-Term Debt declined from Dec. 2023 ($5.57 Mil) to Dec. 2024 ($2.40 Mil) but then increased from Dec. 2024 ($2.40 Mil) to Dec. 2025 ($2.41 Mil).

Creo Medical Group  (OTCPK:CMEOF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Creo Medical Group Long-Term Debt Related Terms

Creo Medical Group Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group Long-Term Debt Chart

Creo Medical Group Annual Data
Trend Feb15 Feb16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.04 5.97 5.57 2.40 2.41

Creo Medical Group Semi-Annual Data
Feb15 Feb16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.57 0.00 2.40 0.00 2.41
CMEOF
53GF Score
Creo Medical Group PLC CMEOF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $2.41 Mil mean?
Creo Medical Group (CMEOF) has a Long-Term Debt of $2.41 Mil as of Dec. 2025.
Is Creo Medical Group's Long-Term Debt too high?
Creo Medical Group's current Long-Term Debt is $2.41 Mil. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Long-Term Debt compare to ABT and SYK?
Creo Medical Group's Long-Term Debt of $2.41 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Creo Medical Group's current Long-Term Debt is $2.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Long-Term Debt of $2.41 Mil. The stock's GF Value™ is $0.24, compared to a current price of $0.20 — trading 16.7% below its estimated fair value. The current Long-Term Debt is $2.41 Mil. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Long-Term Debt is $2.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.20 is trading 16.7% below its estimated GF Value™ of $0.24.

Key valuation signals for CMEOF:

  • Long-Term Debt: $2.41 Mil
  • GF Value™: $0.24 vs. price of $0.20 (16.7% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score

Get the complete analysis for CMEOF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.24
GF Value